Alteogen Eyes First-Mover Advantage For Eylea Biosimilar
Cites Benefit Of Formulation Patent As Aflibercept Rival Completes Phase I Trial
Korea’s Alteogen believes that formulation patents granted in the EU, US and Japan as well as a pending process patent may offer it a first-mover advantage on biosimilar aflibercept. The firm has just completed a Phase I trial for its proposed rival to Eylea.
You may also be interested in...
Sandoz Ups Biosimilar Game With Alteogen Subcutaneous Tech Deal
Sandoz is eyeing development of up to three subcutaneous formulation biosimilars, which offer greater benefits to both patients and healthcare providers, via a technology agreement with Korean firm Alteogen.
Alvotech Kicks Off Trials For Eylea Biosimilar
Alvotech has announced the start of clinical trials for its AVT06 proposed aflibercept biosimilar rival to Eylea, joining a host of other developers pursuing the same target.
Sandoz Reveals Aflibercept Program
Sandoz has revealed late-stage clinical development plans for an aflibercept biosimilar, setting out details of a Phase III trial for the proposed Eylea rival.